French reimbursement: US approves, wants more changes
This article was originally published in Clinica
US industry has given the thumbs up to imminent changes in the French reimbursement system for devices used in private hospitals. It has been actively trying to influence the way the new medical technology assessment body (CEDM - see this issue p 4) will work within the new reimbursement system. It has also circulated article-by-article comments on the latest draft decree on setting up CEDM to high-level government officials in France.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.